drugset / Trial / NCT02336698

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002

NCT02336698

Phase 3 Completed 18 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as Monotherapy compared with placebo in participants with signs and symptoms of osteoarthritis of the hip or knee that are not adequately controlled by current pain therapy.

Timeline

Start
2015-07-13
Primary completion
2016-09-15
Completion
2016-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Fulranumab Monoclonal antibody 1 mg Subcutaneous
Subject Fulranumab Monoclonal antibody 3 mg Subcutaneous

Indications